TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17493004
Drug: Curcumin 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 30 mg b.i.d., bovine lactoferrin 100 mg b.i.d., N-acetylcysteine 600 mg b.i.d., pantoprazole 20 mg b.i.d.
Study: 15833589
Drug: Cortisol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (0.2 mg/kg)
Study: 15833589
Drug: Cocaine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0.2 mg/kg)
Study: 12042201
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus fluoxetine (10 mg/day olanzapine, 20 mg/day fluoxetine)
Study: 12042201
Drug: Olanzapine plus
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine plus placebo (10 mg/day olanzapine, placebo)
Study: 2652217
Drug: Cimetidine (CMT)
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine (CMT) 400 mg/night
Study: 2652217
Drug: Ranitidine (RNT)
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine (RNT) 150 mg/night
Study: 1100308
Drug: Intramuscular phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular phenytoin
Study: 28191694
Drug: RCT sample
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT sample treatment effects (weighted)
Study: 10827334
Drug: 1-implant group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-implant group
Study: 28389025
Drug: 2-implant group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-implant group
Study: 10827334
Drug: Nestorone(R) implants
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nestorone(R) implants
Study: 26916733
Drug: MDCO-216 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-216 (5, 10, 20, 30, and 40 mg/kg) infused over 2 hours
Study: 26916733
Drug: MDCO-216 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-216 (high doses)
Study: 24373344
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) - 3 monthly injections of 1.25 mg
Study: 24373344
Drug: Intravitreal triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal triamcinolone (IVT) - 2 injections of 2 mg 2 months apart
Study: 17497754
Drug: Sample preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sample preparation (liquid‐liquid extraction)
Study: 11862975
Drug: Chronic alacepril
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic alacepril treatment (12 weeks)
Study: 11862975
Drug: Acute alacepril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute alacepril treatment
Study: 7554760
Drug: L-arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (10 g, systemic infusion, n = 5)
Study: 7554760
Drug: D-arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-arginine (10 g, systemic infusion, n = 3)
Study: 7554760
Drug: L-arginine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (40 mumol/l, forearm vascular bed infusion)
Study: 7554760
Drug: D-arginine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-arginine (40 mumol/l, forearm vascular bed infusion)
Study: 30543339
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus standard-of-care treatment beyond disease progression
Study: 26854355
Drug: 3-module group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-module group treatment (cognitive, exposure, skills) for PTSD
Study: 22919989
Drug: 0.1% Tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% Tacrolimus ointment twice a day
Study: 22919989
Drug: 0.05% Clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% Clobetasol propionate ointment once a day
Study: 20090326
Drug: Control sugar
Normalized name: Meta Appetite Control Sugar-Free Powder for Suspension (Orange Zest)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control sugar (65% sucrose + 33% glucose syrup)
Study: 2495891
Drug: Triphasic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic preparation
Study: 28139259
Drug: Dalteparin 5000
Normalized name: dalteparin 5000 intl units/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 5000 units daily for 12 weeks
Study: 16555157
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN group, n=20)
Study: 11263281
Drug: Drug-penetration and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-penetration and oral administration of traditional Chinese decoction plus traction
Study: 11263281
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Chinese decoction and traction
Study: 8644682
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (60 mg Fe/d)
Study: 8644682
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (120 mg Fe/wk)
Study: 8644682
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation (60 mg Fe/d) in subgroup (n = 45)
Study: 8644682
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron supplementation (120 mg Fe/wk) in subgroup (n = 54)
Study: 8644682
Drug: Compliance in
Normalized name: B-12 Compliance Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance in daily group
Study: 8644682
Drug: Compliance in
Normalized name: B-12 Compliance Injection Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance in weekly group
Study: 1687121
Drug: Alpidem 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem 200 mg
Study: 1687121
Drug: Alpidem (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpidem (all doses)
Study: 6347123
Drug: Dihydroergotamine mesylate
Normalized name: Dihydroergotamine Mesylate
DrugBank: Dihydroergotamine (DB00320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dihydroergotamine mesylate with low-dose heparin sodium
Study: 6390998
Drug: Low-dose heparin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose heparin alone
Study: 30772343
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of freshly collected autologous adipose tissue
Study: 28816707
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise with brace adjustment twice per week
Study: 27431233
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg tribendimidine (study 1)
Study: 27431233
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tribendimidine (study 2)
Study: 27431233
Drug: ≥100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ≥100 mg tribendimidine
Study: 24158761
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel daily for 6 months
Study: 16248463
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment in the other nasal cavity)
Study: 12092987
Drug: 1% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% CHX gel (single professional tooth cleaning)
Study: 12092987
Drug: 1% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% CHX gel (daily tooth brushing for 2 weeks)
Study: 22288298
Drug: L-arginine 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 6 g/24-hour
Study: 22288298
Drug: L-arginine 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine 12 g/24-hour
Study: 11283865
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (IFN + AMA)
Study: 3102127
Drug: Suprofen (prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprofen (prostaglandin synthetase inhibitor)
Study: 28081351
Drug: Methylprednisolone 15
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 15 mg/kg
Study: 23570596
Drug: Half-dose triptorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose triptorelin (1.875 mg each time)
Study: 18654731
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bladder retraining and anticholinergic drugs
Study: 16905197
Drug: Reinforcement schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement schedule with reset in reinforcer magnitude for a positive drug test
Study: 12546342
Drug: Clemastine (0.68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine (0.68 mg), pseudoephedrine (60 mg), and acetaminophen (1,000 mg)
Study: 11115196
Drug: Pseudoephedrine and
Normalized name: Pseudoephedrine and terfenadine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine and acetaminophen
Study: 8894261
Drug: Cilazapril (2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (2.5-5 mg/day)
Study: 6347746
Drug: Oxyphenbutazone (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxyphenbutazone (400 mg/day)
Study: 23406290
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g amoxicillin one hour pre-operatively
Study: 23406290
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules 1 hour pre-operatively
Study: 19460761
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (anakinra 100 mg/day + pegsunercept 800 microg/kg twice a week)
Study: 19460761
Drug: Monotherapy (anakinra
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (anakinra 100 mg/day)
Study: 16826487
Drug: Intradermal skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal skin test with heat-inactivated Lancy-Vaxina
Study: 16826487
Drug: Positive neutralizing
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive neutralizing antibody
Study: 10890632
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg afelimomab three times daily over 3 days
Study: 3922887
Drug: Commercial diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial diet preparation 1
Study: 3922887
Drug: Commercial diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial diet preparation 2
Study: 27912954
Drug: Dietary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary and lifestyle recommendations based on Iranian traditional medicine (ITM) for 3 months
Study: 16253773
Drug: Amifostine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (200 mg/m2 i.v.) administered 15-30 min before each fraction of radiation
Study: 28443835
Drug: 10% boric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% boric acid solution
Study: 28443835
Drug: 5% boric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% boric acid solution at 55°C for 60s
Study: 2427837
Drug: Celiprolol 600
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 600 mg
Study: 2427859
Drug: Celiprolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (all doses)
Study: 30146932
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (1-g capsules daily)
Study: 17162995
Drug: 200‐mg modafinil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg modafinil
Study: 3723795
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion of 700 ml at a rate of 5 ml/min
Study: 3723795
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg administered immediately before transfusion
Study: 24608198
Drug: Intermittent oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermittent oxaliplatin (IO) administration (eight‐cycle blocks of oxaliplatin treatment)
Study: 24608198
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and magnesium salts (Ca/Mg)
Study: 24608198
Drug: Continuous oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous oxaliplatin (CO) administration
Study: 19477537
Drug: G-CSF (Filgrastim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (Filgrastim) at a dose of 10 μg/kg body weight/day subcutaneously
Study: 19477537
Drug: G-CSF and
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF and Placebo
Study: 23278517
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (locator)
Study: 22348650
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control condition (online supportive therapy)
Study: 18516353
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate supplementation (170 mg of calcium lactate and 60 mg of vitamin C, one tablet three times a day for four weeks)
Study: 14616171
Drug: MKC-733 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MKC-733 (4 mg)
Study: 10539777
Drug: Antioxidant mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant mixture (440 alpha‐TE, 2000 RE of beta‐carotene, 500 mg ascorbic acid, 100 microg selenium, 30 mg zinc daily)
Study: 10539777
Drug: Single antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antioxidant supplements (Vitamin E, Vitamin A, Vitamin C)
Study: 8644907
Drug: Special vessels
Normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special vessels and chlorine (5% calcium hypochlorite solution)
Study: 1751573
Drug: Control measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control measurement (1 week before treatment)
Study: 6805119
Drug: Complete parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete parenteral nutrition for 2 days preoperatively and 6 days postoperatively
Study: 6805119
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no parenteral nutrition)
Study: 17375114
Drug: Complete parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete parenteral nutrition
Study: 28949260
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg CoQ10 per day for 12 weeks
Study: 8249842
Drug: piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piretanide 6 mg + ramipril 5 mg
Study: 8249842
Drug: piretanide 3
Normalized name: piretanide 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piretanide 3 mg
Study: 8249842
Drug: piretanide 6
Normalized name: piretanide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piretanide 6 mg
Study: 8249842
Drug: ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 2.5 mg
Study: 8249842
Drug: ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 10 mg
Study: 2938471
Drug: Flurbiprofen 150
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 150 mg per day for 6 days
Study: 2938471
Drug: Flurbiprofen 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 200 mg per day for 3 weeks
Study: 2938471
Drug: Flurbiprofen 400
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen 400 mg per day for 7 days
Study: 18493882
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (n=28)
Study: 18493882
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (n=32)
Study: 12593522
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 3,200 microg day(‐1) b.i.d.
Study: 12593522
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) suspension for nebulization 1,600 microg day(‐1) b.i.d.
Study: 12593522
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate (BDP) 800 microg day(‐1) b.i.d. via metered-dose inhaler (MDI) plus spacer
Study: 9445198
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (18 g of omega-3 polyunsaturated fatty acids, PUFA)
Study: 7632640
Drug: Estraderm TTS
Normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estraderm TTS 100 micrograms twice weekly
Study: 7632640
Drug: Estraderm TTS
Normalized name: ESTRADERM TTS
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estraderm TTS 200 micrograms twice weekly
Study: 319816
Drug: Fentanyl 0.05
Normalized name: fentanyl 0.05 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.05 mg
Study: 24252064
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments in the hospital (Control group)
Study: 20369558
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of improved sex therapy and oral sildenafil for 3 months
Study: 20369558
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil alone for 3 months
Study: 12456446
Drug: Gabapentin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (15 mg/kg/day in 3 divided doses)
Study: 10546710
Drug: Outpatient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient therapy with two 1-g doses of intramuscular ceftriaxone at 24-hour intervals followed by oral cephalexin
Study: 10546710
Drug: Inpatient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient therapy with two 1-g doses of intramuscular ceftriaxone at 24-hour intervals followed by oral cephalexin
Study: 10546710
Drug: Outpatient therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient therapy
Study: 7573232
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms of thyrotropin‐releasing hormone
Study: 7573232
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms of thyrotropin‐releasing hormone
Study: 2347114
Drug: 1% ciclopiroxolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% ciclopiroxolamine solution applied once daily for 1, 2, or 3 days
Study: 6670732
Drug: Fentanyl (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.1 mg) and Atropine (0.01 mg/kg b.w.)
Study: 6670732
Drug: Innovar (Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovar (Fentanyl (0.1 mg) and Droperidol (5 mg))
Study: 6670732
Drug: Innovar (Fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Innovar (Fentanyl (0.1 mg) and Droperidol (5 mg)) plus Atropine (0.01 mg/kg b.w.)
Study: 27510595
Drug: BAI 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAI 320 μg/day
Study: 27510595
Drug: BAI 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAI 640 μg/day
Study: 27510595
Drug: MDI 640
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI 640 μg/day
Study: 24702835
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg per day) plus folic acid
Study: 24702835
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg per day) plus folic acid in original stratum
Study: 24702835
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg per day) plus folic acid in expanded stratum
Study: 15848537
Drug: Daclizumab induction
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclizumab induction (2 mg/kg) on PTD 0 and 14
Study: 15848537
Drug: Thymoglobulin induction
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin induction (1.5 mg/kg) on PTD 0 and 2 followed by daclizumab on POD 14
Study: 12222700
Drug: Pravastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (40 mg/day) therapy adjunctive to thrombolytic therapy
Study: 7714788
Drug: Intravenous caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous caffeine (0, 37.5, 75, 150 or 300 mg/70 kg)